홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Leniolisib

HCID 57495353
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
1354690-24-6
표준 SMILES
CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1
InChIKey
MWKYMZXCGYXLPL-ZDUSSCGKSA-N
분자식
C21H25F3N6O2
평균 분자량
450.5 g/mol
단동위원소 질량
450.19910855

개요

Leniolisib is a pyridopyrimidine that is 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine substituted by [(3S)-1-propanoylpyrrolidin-3-yl]amino and 6-methoxy-5-(trifluoromethyl)pyridin-3-yl groups at positions 4 and 6, respectively. It has a role as an EC 2.7.1.153 (phosphatidylinositol-4,5-bisphosphate 3-kinase) inhibitor and an immunomodulator. It is a tertiary carboxamide, a member of pyridines, an aromatic ether, an organofluorine compound, a member of pyrrolidines, a pyridopyrimidine and a secondary amino compound.

이름 및 식별자

우선 이름
Leniolisib
IUPAC
1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one
영어명
Leniolisib
분자식
C21H25F3N6O2
분자량
450.46

이름 및 동의어

Leniolisib1354690-24-6Cdz173 free baseCdz-173 free baseCDZ173-NXleniolisibumCDZ-173-NXL22772Z9CP1-[(3S)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one1-Propanone, 1-((3S)-3-((5,6,7,8-tetrahydro-6-(6-methoxy-5-(trifluoromethyl)-3-pyridinyl)pyrido(4,3-d)pyrimidin-4-yl)amino)-1-pyrrolidinyl)-1-((3S)-3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-7,8-dihydro-5H-pyrido(4,3-d)pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-oneRefChem:57738
이름 더 보기
CDZ 173CS-2818leniolisib(CDZ 173)CDZ173CDZ-173CDZ 173Rupatadine Impurity 2-d8Leniolisib, 10 mM in DMSOleniolisib (CDZ 173) ,S8752inhibit,Inhibitor,Phosphoinositide 3-kinase,Leniolisib,PI3K,CDZ-173,CDZ 173
(S)-1-(3-((6-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)propan-1-oneLeniolisib [INN]Leniolisib free baseMFCD30470232leniolisib (CDZ 173)C21H25F3N6O2Leniolisib (CDZ173)Leniolisib; CDZ173

물성

구조 계산 물성보충 중

XLogP
2.5
극성 표면적
83.5 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
10
회전 가능 결합 수
5
무거운 원자 수
32
형식 전하
0
복잡도
654

실험 및 물리화학적 성질

Solubility<1 mg/mL
Human Drugs · 2건

Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

EMA approved medicines: Human medicine (Orphan designations)

물리화학적 성질

저장 조건
-20 °C · Store at -20°C
용해도
DMF:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.11(Max Conc. mM)DMSO:71.67(Max Conc. mg/mL);159.09(Max Conc. mM)Ethanol:16.5(Max Conc. mg/mL);36.63(Max Conc. mM)
물리적 상태
결정성 고체
색상
White to off-white

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Hepatotoxicity · 1건

In the prelicensure clinical trials of leniolisib in patients with APDS, ALT elevations were rarely described, and there were no reports of hepatic adverse events or discontinuations because of abnormal liver tests. Intermittent elevations in liver enzymes are not uncommon in patients with untreated APDS due to bacterial, viral and opportunistic infections. Since its approval in the United States, there have been no reported cases of clinically apparent liver injury associated with leniolisib therapy, but the drug has had very limited clinical use.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

화학 및 산업

약리 정보

ATC Code · 2건

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingLeniolisib is 94.5% bound to plasma proteins.
Pharmacodynamics · 1건

Leniolisib works to block aberrant PI3Kδ-dependent signalling pathways of immune cells, such as B and T cells, neutrophils, monocytes, basophils, plasmocytoid dendritic cells, and mast cells. _In vitro_, leniolisib dose-dependently suppresses the PI3Kδ pathway hyperactivation in cell lines overexpressing p110δ mutants and in primary immune cells from patients with APDS. _Ex vivo_ pharmacodynamics of leniolisib in the proportion of phosphorylated Akt (pAkt)- positive B cells were assessed intra-individually at 10, 30, and 70 mg twice daily for four weeks at each dose level in patients with APDS. Within the explored dose range, higher leniolisib plasma concentrations were generally associated with a higher reduction of pAkt-positive B cells. Higher doses were associated with a slightly higher peak and more sustained reduction. Treatment with leniolisib 70 mg twice a day at a steady state is estimated to produce a time-averaged reduction of pAkt-positive B cells by approximately 80%.

Mechanism of Action · 1건

Phosphoinositide-3-kinase δ (PI3Kδ) is a lipid kinase activated downstream of tyrosine kinase receptors and G-protein–coupled receptors in immune cells. It mediates the PI3K/AKT pathway, which is involved in cell proliferation, growth, and survival. A heterodimer made up of a regulatory subunit (p85α) and a catalytic subunit (p110δ), PI3Kδ is primarily expressed on hematopoietic cells such as lymphocytes and myeloid cells. It converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3), a signalling molecule that downstream proteins like the AKT kinase, which activate mammalian target of rapamycin (mTOR) complex I and inhibit FOXO family of transcription factors. APDS is associated with gain-of-function variants in the gene encoding p110δ or loss of function variants in the gene encoding p85α, each causing hyperactivity of PI3K-delta, reduced T cell function, lymphadenopathy, and immunodeficiency. Leniolisib inhibits PI3Kδ by blocking the active binding site in the p110δ subunit. In cell-free isolated enzyme assays, the selectivity was higher for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAKT pathway activity and inhibited proliferation and activation of B and T cell subsets. Leniolisib inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/AKT pathway, and the dysregulation of B and T cells.

관련 반응

2건
반응 기록 만들기
HRID 242340 반응식
HRID 242340생성물로
HRID 242341 반응식
HRID 242341생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
1354690-24-6
PubChem CID
57495353
DTXSID
DTXSID501358746
ChEMBL
CHEMBL3643413
ChEBI
CHEBI:229649
UNII
L22772Z9CP
Biological Half-LifeThe effective half-life is approximately seven hours. The apparent terminal elimination half-life is approximately 10 hours.
Metabolism/Metabolites · 1건

About 60% of leniolisib is metabolized by the liver. Leniolisib undergoes oxidative metabolism, which is primarily mediated by CYP3A4 (94.5%), as well as CYP3A5 (3.5%), CYP1A2 (0.7%) and CYP2D6 (0.7%) to a minor extent. Few metabolites of leniolisib have been characterized in one study; however, no metabolites were abundant in plasma relative to the parent drug. Other metabolic pathways include dealkylation, demethylation, and hydroxylation. Other suggested excretion routes include intestinal secretion by BCRP and CYP1A1-mediated extrahepatic metabolism.

FDA Pharmacological Classification · 6건

L22772Z9CP

LENIOLISIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Phosphoinositide 3-Kinase delta Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 1A2 Inhibitors

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

MeSH Pharmacological ClassificationAgents that inhibit PHOSPHOINOSITIDE-3 KINASE activity.
Absorption, Distribution and Excretion · 4건

The systemic drug exposure (AUC and Cmax) of leniolisib increases dose proportionally. During twice daily dosing approximately 12 hours apart, leniolisib accumulates approximately 1.4-fold (range of 1.0 to 2.2) in achieving steady-state. Steady-state drug concentrations can be expected to be reached after approximately two to three days. The Tmax is about one hour. Food has negligible effects on the systemic exposure of leniolisib.

The mean recovery of total 14C-radioactivity following a single oral dose of 70 mg <sup>14</sup>C-leniolisib was 92.5% following 168 hours post-dose. About 67% and 25.5% of the recovered dose were in feces and urine, respectively. Of the recovered dose in urine, 6.32% was in unchanged parent drug form and the predominant drug-related material.

The systemic decay in leniolisib plasma concentration over time is bi-exponential, indicating a distribution delay toward peripheral tissues. The volume of distribution of leniolisib is estimated to be 28.5 L in patients with APDS.

In one study, healthy volunteers received leniolisib single ascending doses up to 400 mg and multiple ascending doses up to 140 mg twice daily for 14 days. Oral drug clearance from plasma (CL/F) was 4 L/h.

상·하류 제품 정보

상류 원료

1-Pyrrolidinecarboxylic acid, 3-[[5,6,7,8-tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin-4-yl]amino]-, 1,1-dimethylethyl ester, (3S)-1-Pyrrolidinecarboxylic acid, 3-[[5,6,7,8-tetrahydro-6-(phenylmethyl)pyrido[4,3-d]pyrimidin-4-yl]amino]-, 1,1-dimethylethyl ester, (3S)-1-Pyrrolidinecarboxylic acid, 3-[(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)amino]-, 1,1-dimethylethyl ester, (3S)-6-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[4,3-D]피리미딘5-bromo-2-methoxy-3-(trifluoromethyl)pyridine2-Methoxy-3-(trifluoromethyl)pyridine(S)-(-)-1-tert-부톡시카르보닐-3-아미노피롤리딘2-클로로-3-트리플루오로메틸피리딘프로피온일 염화물